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ABSTRACT
Objectives The Carlos Slim Foundation implemented 
the Integrated Measurement for Early Detection (MIDO), a 
screening strategy for non- communicable diseases (NCDs) 
in Mexico as part of CASALUD, a portfolio of digital health 
services focusing on healthcare delivery and prevention/
management of NCDs. We investigated the disease 
profile of the screened population and evaluated MIDO’s 
contribution to the continuum of care of the main NCDs.
Design Using data from MIDO and the chronic diseases 
information system, we quantified the proportion of the 
population screened and diagnosed with NCDs, and 
measured care linkage/retention and level of control 
achieved. We analysed comorbidity patterns and estimated 
prevalence of predisease stages. Finally, we estimated 
characteristics associated with unawareness and control 
of NCDs, and examined efficacy of the CASALUD model in 
improving NCD control.
Setting Public primary health centres in 27/32 Mexican 
states.
Participants Individuals aged ≥20 years lacking 
healthcare access.
Results From 2014 to 2018, 743 000 individuals were 
screened using MIDO. A predisease or disease condition 
was detected in ≥70% of the population who were 
unaware of their NCD status. The screening identified 
38 417 new cases of type 2 diabetes, 53 133 new cases 
of hypertension and 208 627 individuals with obesity. 
Dyslipidaemia was found in 77.3% of individuals with 
available blood samples. Comorbidities were highly 
prevalent, especially in people with obesity. Only 
5.47% (n=17 774) of individuals were linked with their 
corresponding primary health centre. Factors associated 
with unawareness of and uncontrolled NCDs were sex, 
age, and social determinants, for example, rural/urban 
environment, access to healthcare service, and education 
level. Patients with type 2 diabetes treated at clinics under 
the CASALUD model were more likely to achieve disease 
control (OR: 1.32, 95% CI: 1.09 to 1.61).
Strengths and limitations of this study
 ► The Measurement for Early Detection (MIDO) 
screening strategy contributes to betterment of 
public health by identifying predisease states of the 
most common non- communicable diseases (NCD) 
and thereby allowing early intervention, particular-
ly in disadvantaged populations lacking healthcare 
access.
 ► Another strength of this study is the very large sam-
ple size (743 000 individuals screened over a 4- year 
period).
 ► Although MIDO did not use gold- standard tests for 
diagnosing type 2 diabetes (fasting plasma glu-
cose and oral glucose tolerance tests), the simple 
and accessible approach we used (fasting capillary 
glucose and random capillary glucose) is reliable for 
identifying undiagnosed diabetes as well as predict-
ing individuals at risk.
 ► Possible limitations include the assumptions that 
disease distribution and unawareness are the same 
in the studied population as in the surveys, and that 
all the individuals screened using MIDO could be 
followed within the individual administrative public 
health centre database.
 ► Because of selection bias, the results of the MIDO 
screening cannot be used as an estimate of NCD 
prevalence.
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Conclusion Patient- centred screening strategies such as MIDO are 
urgently needed to improve screening, access, retention and control for 
patients with NCDs.
INTRODUCTION
Non- communicable diseases (NCDs), such as ischaemic 
heart disease, chronic kidney disease and type 2 diabetes 
mellitus (T2DM), are the three leading causes of death 
in Mexico.1 NCDs were responsible for 80% (67 535) of 
total deaths in the country in 2019. T2DM is the leading 
cause of years lived with disability.1 High fasting plasma 
glucose, high body mass index (BMI), high blood pres-
sure and suboptimal diet have been recognised as the top 
risk factors associated with NCDs, accounting for more 
than half of attributable deaths and disability- adjusted 
life- years.1
Although T2DM and hypertension are recognised 
as public health problems, according to the Mexican 
National Health and Nutrition Survey (2016), 40% of 
the population with hypertension and 29% of those with 
T2DM are unaware of their condition.2 3 Moreover, it is 
recognised that only 46% of people with hypertension 
and 16% of people with T2DM achieve control of their 
condition.3 Additionally, lipid disorders contribute to 
the development of NCDs such as cardiovascular disease, 
which has been the main cause of mortality in Mexico 
in recent years. The 2012 Ensanut study reported that 
approximately 31% of Mexican adults had hypercholes-
terolaemia and 49% had hypertriglyceridaemia.4
It is also known that multiple comorbidities are highly 
common in patients with T2DM, especially with increasing 
age.5 Comorbidities, including cardiovascular and neuro-
logical complications, diabetic retinopathy and diabetic 
nephropathy, have been associated with poor health 
outcomes. In the case of patients with cardiovascular 
diseases, disorders of carbohydrate metabolism, thyroid 
disease, bronchial asthma, varicose disease, chronic hepa-
titis and urolithiasis are common in patients with isch-
aemic heart disease or chronic heart failure.6 7 Moreover, 
evidence from other countries suggests that the cost of 
illness is substantially higher for individuals with comor-
bidities and represents a major challenge for healthcare 
systems.8
During the past decade, the Mexican government has 
implemented plans, regulations, policies and programmes 
to tackle NCDs, mainly focusing on nutrition; however, 
few population- based screening programmes have been 
implemented.9 Only two studies have been published 
investigating screening and prevention in primary health-
care at the national level, and these reported little, if any, 
benefit.10 11 Moreover, the traditional screening approach 
only reaches the population already seeking healthcare 
services at health facilities. As a result, nearly half of 
patients with T2DM present tissue damage by the time 
they are diagnosed,12 and a large number of people with 
NCDs remain undiagnosed. In traditional curative health 
systems, the lack of early strategies for NCD detection and 
effective treatments to achieve control and prevent long- 
term complications have been recognised as important 
limitations to prevent microvascular and macrovascular 
complications during the latent period of disease.13 14
To address the aforementioned limitations, in 2008 
the Carlos Slim Foundation (‘Fundación Carlos Slim’) in 
Mexico created an innovative model entitled CASALUD 
(from the Spanish words for ‘CASA’ ‘home’ and SALUD 
‘health’),15 which is an innovative healthcare system lever-
aging digital health resources that includes strategies 
for prevention, early detection and control of the prin-
cipal NCDs based on international best practices. Within 
CASALUD, the Chronic Diseases Information System 
(SIC) and the Integrated Measurement for Early Detec-
tion (MIDO)16 were developed and implemented as 
digital, interconnected platforms enabling health profes-
sionals to perform proactive community- level prevention 
of obesity, T2DM, hypertension and dyslipidaemia (when 
laboratory tests were available).
In this paper, we aim to describe the complete disease 
profile (risk, predisease, disease and comorbidities) of 
the screened Mexican population, and evaluate MIDO’s 
contribution to the continuum of care from screening to 
control of the main NCDs.
METHODS
This analysis included a total of 743 000 people aged ≥20 
years, who were screened by MIDO from 2014 to 2018 in 
137 public primary health centres (PHCs) among 27 of 
the 32 states in Mexico.17 We used data from the MIDO 
and SIC digital platforms, both of which are blinded 
databases of administrative records. As all data were 
anonymised prior to access, informed consent was not 
required. Permission to use the data was granted by the 
Mexican Ministry of Health, according to a signed agree-
ment between the Ministry and the Carlos Slim Founda-
tion, which stipulates that the Foundation may perform 
technical analyses to inform about the progress of the 
NCD programmes in order to provide guidance that may 
contribute to improvements in current policy. Further-
more, this study was conducted in accordance with the 
principles of the Declaration of Helsinki and local laws 
and regulations. SIC enables the registry of medical care 
provided by PHCs to people living with NCDs, including 
information on patient retention, completeness of diag-
nosis and treatment protocols, and metabolic control.
MIDO’s platform focuses on risk assessment of each 
individual based on core measurements such as BMI, 
waist circumference, blood pressure and capillary glucose 
(CG). Data are also collected regarding smoking and 
sleeping habits, as well as responses from the Finnish 
Diabetes Risk Score (FINDRISC) questionnaire.18 Addi-
tionally, in PHCs with laboratory facilities, MIDO assess-
ment also includes a lipid panel. Details on the MIDO 
assessment strategy are described in online supplemental 
figure 1.
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Individuals are classified as having a disease if they 
reported a history of prior diagnosis. A previous diagnosis 
of T2DM or hypertension was identified by self- report if 
the individual knew about their condition. For T2DM, 
individuals are classified as having a new diagnosis if 
their fasting CG was ≥126 mg/dL or a random CG value 
was ≥200 mg/dL.19 For hypertension, the cut- off point is 
systolic blood pressure (SBP) ≥140 mm Hg or diastolic 
blood pressure (DBP) ≥90 mm Hg20; for obesity, the 
threshold is BMI ≥30 kg/m2.21 Dyslipidaemia is defined 
as total cholesterol ≥200 mg/dL and low- density lipo-
protein (LDL) >70 mg/dL, high- density lipoprotein 
(HDL) <40 mg/dL for men (<50 mg/dL for women) or 
hypertriglyceridaemia (triglycerides≥150 mg/dL).22 The 
same thresholds are used for both diagnosis and control 
of hypertension and dyslipidaemia. T2DM control is 
defined in screening as having a fasting CG <130 mg/dL23 
or random CG <140 mg/dL,24 and glycated haemoglobin 
(A1c)<7% in the PHC medical records.23
The ‘predisease’ stage includes individuals identi-
fied with pre- T2DM (fasting glucose 100–125 mg/dL),19 
prehypertension (SBP 130–139 mm Hg or DBP 85–89 mm 
Hg)25 and preobesity (overweight; BMI 25–29.9 kg/m2).26 
Comorbidities are defined as the presence of more than 
one diagnosis or prediagnosis within the same individual. 
Finally, individuals are classified as ‘disease not diagnosed’ 
when all previously mentioned values and measurements 
fell within normal ranges.
Laboratory tests are only included in PHCs with labora-
tory facilities and in those individuals who self- reported 12 
hours of fasting. Lipid profile is measured using a venous 
blood sample for at least one parameter: total cholesterol, 
LDL cholesterol, HDL cholesterol and triglycerides.
MIDO includes an algorithm to profile the risk of each 
individual, which enables health professionals to provide 
counselling to patients and prescribe changes in lifestyle. 
In addition, individuals who are identified as having 
an NCD but are unaware of their disease before MIDO 
screening are referred to their corresponding PHC for 
further confirmation and clinical management. We 
applied the continuum of care framework to identify and 
quantify the flow of people, through all stages; namely, 
detection, treatment and control.
Statistical analysis
First, we conducted a descriptive analysis of the main 
sociodemographic characteristics and disease profiles of 
the screened population, using mean±SD or frequency 
and proportion (%), according to the scale of the vari-
able. The distributions of diseases, prediseases and lipid 
profiles were estimated as proportions, and then strati-
fied according to the three categories of the MIDO inte-
grated risk assessment score: <10 points, low; >10 and<13, 
moderate and >13, high (based on the FINDRISC scale,18 
to estimate the sensitivity and specificity by category. 
Missing data were not imputed.
We then described the continuum of care using logistic 
regression models to evaluate factors associated with a 
lack of awareness and control among people with hyper-
tension or diabetes. Finally, we evaluated the contribution 
of CASALUD in closing the gap with respect to disease 
control for those who sought medical care at a PHC. To 
compare PHCs with and without CASALUD, a logistic 
regression model was fitted, in which the dependent vari-
able was achieving control (glycated haemoglobin (A1c), 
CG, blood pressure or total cholesterol levels). Models 
were adjusted according to sex, age, time since diagnosis, 
number of medical visits, and comorbidities. A p <0.05 
was considered statistically significant, and all analyses 
were performed using Stata V.15 (StataCorp).27
Patient and public involvement
Neither patients nor the public were involved in the 
design of this research.
RESULTS
Table 1 shows the principal characteristics of the popu-
lation screened using MIDO (N=743 000; approximately 
55% of the total population covered by the 137 PHCs). 
The average age was 41.5 (SD 14.8) years; nearly half of 
the population (49.2%) was between 20 and 39 years. 
Nearly 70% of screened individuals were women, and 
almost 11% reported being an active smoker. Parental 
history of T2DM was identified in 22.5% of the popula-
tion. Based on MIDO’s integrated risk assessment, 35.1% 
of the population was classified as having a high risk of 
disease, 16.2% was classified as having moderate risk, and 
48.5% were identified as having low risk.
The overall disease profile of the population screened 
using MIDO was as follows: 89.8% of the population had 
a disease or predisease condition (reported by previous 
diagnosis or identified during the screening). Less than 
5% of screened individuals had a previous diagnosis of 
T2DM or hypertension, with controlled and uncon-
trolled values in the same proportion. One- third of 
those screened had a disease newly diagnosed by MIDO 
(T2DM, hypertension, obesity or dyslipidaemia), and half 
of the population had a predisease diagnosis (pre- T2DM, 
prehypertension or preobesity/overweight) (table 2).
The number of comorbidities was higher with increased 
age and among women. Among people with obesity (the 
most common diagnosis at 29.4% of the screened popula-
tion), the rates of comorbidities were as follows: 21.29%, 
no comorbidity; 4.13%, comorbid with hypertension; 
1.54%, T2DM; 0.36%, dyslipidaemia; 0.65%, T2DM and 
hypertension; 0.06%, hypertension and dyslipidaemia; 
0.04%, T2DM and dyslipidaemia; and 0.01%, T2DM, 
hypertension and dyslipidaemia.
Nearly 30% of the population had obesity and 37.5% 
had preobesity (overweight) at the time of screening. In 
the case of T2DM, 4.1% of cases were previously diag-
nosed and fewer than 40% were controlled, according 
to CG results. T2DM was detected in 5.8% (38,417 indi-
viduals) of the population screened with MIDO, and pre- 
T2DM was identified in 13.4%. Regarding hypertension, 
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6.1% of individuals had a previous diagnosis, and 
nearly 60% had blood pressure values considered to be 
adequately controlled. Hypertension was diagnosed using 
MIDO in 7.4% (53,133 individuals) of the population and 
19.2% were diagnosed with prehypertension (table 2). 
Regarding individuals’ lipid profiles (laboratory tests, 
n=38 855), 77.3% had at least one type of dyslipidaemia, 
with low HDL cholesterol being the most common type 
(67.2%), followed by hypertriglyceridaemia (46.5%) and 
high total cholesterol (27.6%), as shown in table 2.
Males and people who were younger, non- smokers, 
overweight or obese, without a parental history of T2DM, 
lived in urban municipalities, lacked access to health 
services and with lower education levels were more likely 
to be unaware that they were living with T2DM (table 3). 
Similar factors were found for hypertension unawareness, 
but older age and rural residence were also commonly 
observed. In people with a previous diagnosis of T2DM, 
poor glucose control was more likely in men, older 
people, nonsmokers, individuals with a parental history 
of T2DM, those with obesity and residents of rural munic-
ipalities (table 3).





   Female 516 577 (69.5)
   Male 226 423 (30.5)
  Age (years)* 41.5±14.8
   20–39 345 929 (49.2%)
   40–59 265 699 (37.8%)
   ≥60 91 220 (13%)
Lifestyle and risk factors
  Smoking (yes, within past 12 months)† 75 520 (10.7)
  Parental history of diabetes‡ 141 363 (22.5)
Anthropometrics
  Height (cm) 159.1±16.3
  Weight (kg) 70.5±15.3
  BMI (kg/m2) 27.8±5.3
  Waist circumference, cm 91.5±13.8
Biomarkers§
  SBP (mm Hg) 116.8±16.8
  DBP (mm Hg) 72.2±11.2
  Fasting CG (mg/dL) 104.4±41.4
  Non fasting CG (mg/dL) 116.4±50.1
  Total cholesterol (mg/dL) 171.1±51.9
  LDL cholesterol (mg/dL) 90.9±30.8
  Triglycerides (mg/dL) 178.3±100.7




§Lipid profile was measured in only 5% of the sample (n=38 855).
BMI, body mass index; CG, capillary glucose; DBP, diastolic 
blood pressure; LDL, low- density lipoprotein; MIDO, Integrated 
Measurement for Early Detection; SBP, systolic blood pressure.
Table 2 MIDO screening results
Population screened (N=743 000) n (%)
  Previous disease,* controlled 32 234 (4.3)
  Previous disease,* uncontrolled 30 912 (4.2)
  Disease detected†‡ 273 170 (36.8)
  Predisease detected†§ 393 742 (53.0)
  Disease not detected 190 832 (25.7)
Screening of nutritional status according to 
BMI classification (N=709 635)
  Underweight 8575 (1.2)
  Normal weight 226 575 (31.9)
  Overweight (preobesity) 265 858 (37.5)
  Obesity 208 627 (29.4)
Screening of hypertension (N=718 003)
  Normal 484 016 (67.4)
  Controlled hypertension (previous 
diagnosis)
25 566 (3.6)
  Uncontrolled hypertension (previous 
diagnosis)
17 652 (2.5)
  Hypertension (new diagnosis) 53 133 (7.4)
  Prehypertension 137 636 (19.2)
Screening of T2DM (N=660 874)
  Normal 507 087 (76.7)
  Controlled T2DM (previous diagnosis) 10 437 (1.6)
  Uncontrolled T2DM (previous diagnosis) 16 668 (2.5)
  T2DM (new diagnosis) 38 417 (5.8)
  Pre- T2DM 88 265 (13.4)
Screening of dyslipidaemia¶
  Any dyslipidaemia (N=39 335) 30 415 (77.3)
  High total cholesterol (N=38 855) 10 704 (27.6)
  High LDL cholesterol (N=9317) 3472 (37.3)
  Low HDL cholesterol (N=22 861) 15 353 (67.2)
  Hypertriglyceridaemia (N=35 394) 16 445 (46.5)
*Includes T2DM or hypertension.
†In total, 74.4% of the screened population first became aware of 
having a disease or predisease through MIDOscreening.
‡Includes T2DM, hypertension, dyslipidaemia and obesity.
§Includes pre- T2DM, prehypertension and overweight.
¶Lipid profile assessment is not part of the core measurements of 
MIDO. It was measured only in PHCs with laboratoryfacilities.
BMI, body mass index; HDL, high- density lipoprotein; LDL, low- 
density lipoprotein; MIDO, Integrated Measurement for Early 
Detection; SBP, systolic blood pressure; T2DM, type 2 diabetes 
mellitus.
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We found that the MIDO integrated risk assessment 
was a useful way to detect NCDs and prediseases in this 
population. The disease profile distribution is presented 
in table 4. People without a disease diagnosis were mostly 
categorised as having a low risk of disease (90.06%), and 
only 2.61% were categorised as having high risk. Among 
those participants with predisease, 43.13% and 48.71% of 
people with pre- T2DM and prehypertension were cate-
gorised as high risk, respectively; for preobesity (over-
weight), 27.88% had moderate risk and nearly the same 
proportion (26.65%) were categorised as having high 
risk. The majority (83.4%) of people with obesity were 
classified as high risk. More than half of individuals with a 
new diagnosis of T2DM or hypertension were in the high- 
risk group (55.78% and 59.14%, respectively). Finally, 
approximately half of participants with an altered lipid 
profile were categorised as high risk.
Continuum of care
Among all individuals screened using MIDO who 
received a new diagnosis of at least one NCD, only 5.47% 
(n=17 774) sought health services for treatment at a PHC, 
according to SIC records; this represents a proportion of 
94.6% with a treatment gap. Only 23.1% of the popula-
tion treated for T2DM had achieved acceptable glycaemic 
control (A1c<7%), 40.1% of patients treated for hyper-
tension achieved a normal blood pressure, fewer than 
20% of patients treated for dyslipidaemia had decreased 
total cholesterol levels, and only 4.6% of patients treated 
for obesity reduced their weight (online supplemental 
figure 2). Further, the median number of days until 
Table 3 Factors associated with unawareness of and uncontrolled T2DM and hypertension among the population screened 
using MIDO
T2D Hypertension
Unawareness Uncontrolled Unawareness Uncontrolled
n=48 953 n=19 348 n=74 028 n=32 689
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Sociodemographic characteristics
  Sex
   Female (reference) 1.00 1.00 1.00 1.00
   Male 1.16 (1.12 to 1.21) 1.13 (1.06 to 1.21) 1.44 (1.39 to 1.49) 1.33 (1.27 to 1.4)
  Age (years)
   20–39 (reference) 1.00 1.00 1.00 1.00
   40–59 0.88 (0.83 to 0.92) 2.15 (1.99 to 2.34) 0.8 (0.77 to 0.83) 1.84 (1.72 to 1.96)
   ≥60 0.92 (0.87 to 0.98) 1.76 (1.61 to 1.92) 1.26 (1.20 to 1.33) 2.68 (2.50 to 2.87)
Lifestyle and risk factors
  Current smoker
   No (reference) 1.00 1.00 1.00 1.00
   Yes 0.47 (0.44 to 0.50) 0.87 (0.80 to 0.93) 0.88 (0.83 to 0.92) 1.04 (0.99 to 1.09)
  Parental history of diabetes
   No (reference) 1.00 1.00 1.00 1.00
   Yes 0.38 (0.037 to 0.40) 1.25 (1.18 to 1.35) 0.21 (0.21 to 0.23) 1.04 (0.98 to 1.10)
  BMI category
   Normal weight (reference) 1.00 1.00 1.00 1.00
   Overweight (preobesity) 1.09 (1.03 to 1.15) 0.98 (0.91 to 1.07) 1.04 (0.99 to 1.09) 1.28 (1.2 to 1.4)
   Obesity 1.14 (1.08 to 1.20) 1.05 (0.97 to 1.15) 1.06 (1.02 to 1.11) 1.92 (1.80 to 2.06)
Social determinants
  Rural–urban stratification
   Rural (reference) 1.00 1.00 1.00 1.00
   Urban 1.45 (1.38 to 1.52) 0.64 (0.60 to 0.69) 0.92 (0.88 to 0.96) 0.79 (0.74 to 0.83)
   Lacking access to health 
services
1.03 (1.03 to 1.04) 0.99 (0.98 to 0.99) 1.07 (1.06 to 1.08) 0.98 (0.97 to 0.99)
   Low education level 1.02 (1.01 to 1.03) 0.98 (0.98 to 0.99) 1.09 (1.09 to 1.10) 1.02 (1.02 to 1.03)
BMI, body mass index; MIDO, Integrated Measurement for Early Detection; T2DM, type 2 diabetes mellitus.
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starting treatment was 344 (IQR: 124–1708) after having 
received a diagnosis and the first visit to a PHC, with a 
significant difference in days according to disease: 260 
(IQR: 35–649) for T2DM, 323 (IQR: 82–684) for hyper-
tension, 373 (IQR: 108–732) for obesity and 569 (IQR: 
178–903) for dyslipidaemia.
Finally, we found that people who received treatment 
at a PHC that followed the CASALUD model were 32% 
(OR: 1.32, 95% CI: 1.09 to 1.61) more likely than those 
treated at a non- CASALUD PHC to achieve T2DM 
control, adjusting by sex, age, time since detection, time 
since diagnosis, number of medical consultations and 
comorbidities (figure 1). This result was not observed for 
hypertension or dyslipidaemia.
DISCUSSION
This study presents the first findings about the contri-
bution of the MIDO strategy in screening, detection, 
treatment and control of NCDs in the adult Mexican 
population lacking healthcare access. MIDO screening for 
T2DM, hypertension and obesity was achieved in approx-
imately half of the population (N=743 000) covered by 
137 PHCs in 27 states of Mexico. Dyslipidaemia is not 
included in the core measurements of MIDO’s integrated 
risk assessment, but as some PHCs have a laboratory 
facility, lipid profile was included in the analysis of the 
NCD profile, although for only 5.2% of the total screened 
population. The large difference between the proportion 
of people screened for T2DM, hypertension and obesity 
versus those also screened for dyslipidaemia reflects the 
importance of having tools to identify populations at 
risk that can be easily applied in almost any setting, as 
previously recognised (CG, anthropometric measures, 
blood pressure and validated questionnaires such as 
the FINDRISC).28 An advantage of applying validated 
questionnaires is that cut- points can be adapted to the 
local context, to maximise their predictive capacity and 
sensitivity.29
A large proportion of undiagnosed NCDs among the 
screened population were identified using MIDO. Our 
estimations showed that more than half of people with a 
T2DM diagnosis were unaware of their condition. These 
results are aligned with previous estimations; the WHO 
reported that between 24% and 62% of people with 
diabetes in a sample of seven countries were undiagnosed 
and untreated.30 According to the National Health and 
Nutrition Survey, Mexico has an undiagnosed T2DM 
prevalence of 30%.3 In the case of hypertension, our 
Table 4 Distribution of detected disease profiles according to risk category, based on the MIDO questionnaire
Low Moderate High Sensitivity,% Specificity, %
Area under the 
ROC curve in high/
very high risk
coef. (95% CI)
Disease not detected 90.06 7.33 2.61 –
Overweight 45.48 27.88 26.65 –
Pre- diabetes 38.98 17.89 43.13 –
Prehypertension 33.33 17.96 48.71 –
Obesity 6.47 10.14 83.4 –
Type 2 diabetes mellitus 28.21 16 55.78 63.4 66.4 0.65 (0.64 to 0.65)
Hypertension 25.11 15.75 59.14 63.6 68.0 0.55 (0.54 to 0.56)
High total cholesterol 28.8 19.73 51.48 51.5 59.2 0.55 (0.54 to 0.56)
High LDL 35.63 16.94 47.43 46.2 60.8 0.53 (0.52 to 0.54)
Low HDL 30.61 18.08 51.31 47.4 63.9 0.55 (0.54 to 0.56)
High triglycerides 35.68 18.11 46.21 51.3 62.1 0.56 (0.55 to 0.57)
Any dyslipidaemia 34.61 18.63 46.76 46.8 66.7 0.56 (0.55 to 0.57)
HDL, high- density lipoprotein; LDL, low- density lipoprotein; MIDO, Integrated Measurement for Early Detection; ROC, receiver operating 
characteristic.
Figure 1 Control of NCDs at PHCs with versus without 
CASALUD. OR adjusted by sex, age, time from diagnosis, 
number of medical consultations and comorbidities. NCD, 
non- communicable disease; PHC, primary health centre; 
T2DM, type 2 diabetes mellitus.
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results are also aligned with those previously reported 
in the above survey. We found that 55.1% of individuals 
had hypertension, and the National Health and Nutrition 
Survey reported a 40% prevalence of undiagnosed cases.2
Our results confirm that screening is useful for 
detecting people with NCDs. Still, the mean time between 
screening and the first visit to the corresponding PHC was 
more than 1 year. However, this time frame may be some-
what overestimated because some patients screened by 
MIDO may begin treatment in institutions that are not 
interconnected with MIDO, and thus do not share such 
data. On the other hand, we found that more than 90% 
of people diagnosed with NCDs do not attend medical 
visits at a PHC, a fact that is directly considered in the 
treatment gap. Previous analyses have reported that 
rates of participation in a health check among patients 
living with cardiometabolic diseases ranged from 1.2% to 
84.1%.31 Early detection and treatment are essential to 
avoid complications, thereby saving costs for patients and 
for the health system.12 32 33
The lack of awareness about NCD- related symptoms, 
risk factors and lifestyle choices is prevalent.34 35 Studies 
have found that between 30% and 35% of individuals 
living with T2DM were unaware of their disease.36 Male 
sex, family history of T2DM, former smoking, overweight, 
obesity and lack of healthcare access are factors associated 
with unawareness of T2DM; our results are consistent 
with those of other analyses.36 High T2DM unawareness 
increases the rate of poor metabolic control and contrib-
utes to poor management of other diseases, including 
hypertension.37
It is crucial to investigate the reasons people do not 
attend a PHC once they are informed of their disease and 
do not attend their follow- up visits for metabolic control. 
Many studies have reported the following as personal 
barriers: socioeconomic status, lower education level, 
denial of illness, physical disability, patients’ busy schedule 
and time constraints.38 39 Unemployment and low income, 
healthcare access and health services location, health-
care costs, local customs and lack of family support have 
been identified as economic and social barriers.38 Some 
environmental barriers, such as health services location, 
transportation problems and adverse weather conditions 
also contribute to this problem.38 Lastly, barriers related 
to service providers include a failure to respect patients, 
lack of staff, lack of patient follow- up and poor doctor–
patient relationship.39 40 In the Mexican context, a system-
atic review found that the lack of economic resources, 
language barriers (for indigenous populations), and lack 
of healthcare professionals remain important barriers for 
patients with T2DM and hypertension in rural areas of 
Mexico.41
In the present analysis of disease profiles, we found 
that more than half of the population had predisease 
(pre- T2DM, prehypertension or overweight) and more 
than 35% had a disease (T2DM, hypertension, obesity or 
dyslipidaemia); only a quarter of the screened population 
was negative for any of the NCDs screened. The disease 
profiles observed here were not surprising as Mexico has 
one of the highest rates of obesity worldwide (36% in 
2018).42 As expected, comorbidities are common, espe-
cially in older populations. It has been shown that 10% 
and 24% of individuals with obesity have either high 
fasting blood glucose levels (>126 mg/dL) or undiag-
nosed hypertension, respectively.43 Unfortunately, there 
is a lack of information about predisease and the preva-
lence of comorbidities in the Mexican population; one 
previous study in a younger population (age 18–30 years) 
reported results similar to our findings for pre- T2DM, 
with a prevalence of 14.6%.44
Implications for health systems
Complementary to MIDO, the Mexican government and 
the main health systems implemented other strategies 
to prevent and control NCDs, including the national 
strategy ‘Check yourself, measure yourself, move your-
self’ (a mass media campaign launched in 2013) and the 
‘PREVENIMSS’ programme. The former was evaluated 
in 2016, and although the majority of the population 
(57.4%) recognised the campaign and its main compo-
nents,45 it was cancelled after reports showed deficits in 
the implementation and lack of results.11 PREVENIMSS 
was incorporated as a primary care- based integrated 
programme in one of the largest healthcare providers 
(the Mexican Institute of Social Security (IMSS)) in 2002. 
The aim of PREVENIMSS was to reduce the burden of 
disease through preventative services and education, yet 
the evaluation of the impact of this programme revealed 
increases in rates of T2DM and hypertension. The only 
positive impact found was a reduction in mortality rates 
for cervical and breast cancers; this was associated with 
early detection and treatment.10 In the present analysis, 
we show that the MIDO screening strategy contributes to 
the betterment of public health by identifying predisease 
states of the most common NCDs and thereby allowing 
early intervention, particularly in disadvantaged popu-
lations lacking healthcare access. The positive results 
of MIDO arise from the combination of best practices, 
simple and accessible screening tests, and accessibility for 
the public (in and out of PHC settings).
From the perspective of health systems, it is well docu-
mented that an early diagnosis of T2DM will reduce the 
costs related to complications.33 46 There is a large diag-
nosis gap and gap from treatment to control in the case 
of dyslipidaemia because diagnosis and monitoring are 
dependent on a laboratory test. Resource investment 
here is crucial because it has been shown that reductions 
in LDL cholesterol reduce the incidence of heart attack 
and stroke.47
A policy for early NCD identification should include 
a reliable and low- cost screening test, evidence of the 
benefits and costs of screening, and the capacity of the 
health system to identify and then manage the new 
burden of cases.48 In this sense, since 2010, the Mexican 
health normative standards recognise the importance of 
screening for prediagnosis and early diagnosis of T2DM, 
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in people as young as 20 years old and with a screening 
frequency of every 3 years, especially in populations with 
obesity and with first- degree relatives diagnosed with the 
disease.49 Our analysis showed that half of the screened 
population was younger than 40 years old, which is 
alarming as many people in this age group already have 
NCDs and comorbidities.
The present analysis represents a first report of identi-
fied gaps in the continuum of care after the implementa-
tion of MIDO in Mexico. The largest gap in the continuum 
of care is that obesity has not yet been recognised by the 
population as a disease, even though it is highly associated 
with other diseases; moreover, management of obesity 
through weight reduction is not a treatment commonly 
prioritised by health professionals.
Patients who received treatment for T2DM in 
CASALUD PHCs were 32% more likely to achieve 
disease control than patients treated at non- CASALUD 
PHCs. This striking difference suggests that it is possible 
to implement improvements in strategies focused on 
identification, management and control of NCDs at 
the first level of healthcare in Mexico. Furthermore, 
this has become highly relevant during the COVID-19 
pandemic, as diabetes and uncontrolled blood glucose 
have been reported as predictors of severity and mortality 
in COVID-19 patients.50 51 It is well recognised that poor 
glycaemic control and insulin resistance are associated 
with deficits in immunological function, promoting 
inflammatory processes that contribute to mechanisms 
leading to higher risk of infections and worse outcomes 
in patients with T2DM.52 53
Limitations
The results presented here cannot be used as an estima-
tion of the prevalence of NCDs, mainly owing to selec-
tion bias. First, MIDO is not representative of the general 
Mexican population; therefore, the results cannot be 
extrapolated to all Mexican health systems, even though 
this study encompassed a large sample size representing 
the population without healthcare coverage in most 
Mexican states. Because individuals were screened in 
PHC facilities, a selection bias may also exist whereby 
individuals who have a greater likelihood of using health 
services (as patients or as caregivers) are also those with 
the highest propensity to be screened, as observed in the 
distribution according to sex (mainly women). We also 
recognise possible limitations in the estimation of gaps in 
the continuum of care, particularly related to data quality 
and missing data when linking individuals screened using 
MIDO with the individual administrative PHC database, 
SIC.54
It is necessary to recognise that gold standard tests for 
diagnosing T2DM, namely, fasting plasma glucose and 
oral glucose tolerance tests, are not used in MIDO.19 
However, the tests used in screening were fasting CG and 
random CG. This approach is accessible, simple and reli-
able for identifying undiagnosed diabetes; additionally, it 
has been demonstrated that this strategy can be used to 
accurately predict diabetes.28
CONCLUSION
Our study findings reveal that there is an urgent need to 
improve screening, access and retention in care for people 
living with NCDs in Mexico. Because comorbidities are 
common in this population at the time of screening and 
diagnosis, a patient- centred screening strategy, such as 
MIDO, and improved healthcare services are needed to 
achieve effective prevention and management of these 
diseases.
Author affiliations
1Health Sciences University Center (CUCS- UdeG), University of Guadalajara, 
Guadalajara, Jalisco, México
2Carlos Slim Foundation, México City, Mexico
3London School of Hygiene & Tropical Medicine, London, UK
4Institute for Health Metrics and Evaluation, University of Washington, Seattle, 
Washington, USA
5School of Medicine, National Autonomous University of Mexico, Mexico City, Mexico
Acknowledgements We would like to thank the personnel of the Ministry of 
Health of Mexico (National and Local) who facilitated this project’s approval and 
implementation, as well as helped to coordinate with local systems and study 
clinics. We also thank Analisa Avila, of Edanz Pharma, for providing editorial support.
Contributors AM and RSM conceived of and designed the study, acquired 
and interpreted the data, drafted the manuscript and revised the manuscript 
for important intellectual content. HGR and RTC conceived of and designed the 
study, acquired the data and revised the manuscript for important intellectual 
content. AM, LSI, LAMJ and CR acquired, analysed and interpreted the data and 
contributed to writing sections of the manuscript dealing with data analysis. 
RSM and RL conceived and designed the study and revised the manuscript for 
important intellectual content. All authors read and approved of the final version to 
be published and agree to be accountable for all aspects of the work in ensuring 
that questions related to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved.
Funding The MIDO strategy was developed and funded by the Carlos Slim 
Foundation; however, the present study did not receive funding from any third party 
agency, and there is no award or grant number to report.
Competing interests The authors HGR, AM, RSM, RMR, LSI, LAMJ and RTC 
are employed by the Carlos Slim Foundation in Mexico, the developer of MIDO 
and MIDO Plus. RTC is also affiliated with the School of Medicine of the National 
Autonomous University of Mexico (UNAM). CR and RL received compensation from 
the Carlos Slim Foundation for their contributions to this study and the manuscript. 
The authors declare that no other outside funding was received from any other 
organisations and declare no further conflicts of interest.
Patient consent for publication Not required.
Ethics approval Permission to use the deidentified patient data was granted by 
the Mexican Ministry of Health, in accordance with an agreement signed with the 
Carlos Slim Foundation.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available upon reasonable request. The 
data used in this study are available on reasonable request from the corresponding 
author.
Supplemental material This content has been supplied by the author(s). It has 
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been 
peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
9Gallardo- Rincón H, et al. BMJ Open 2021;11:e049836. doi:10.1136/bmjopen-2021-049836
Open access
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iD
Alejandra Montoya http:// orcid. org/ 0000- 0002- 9466- 8452
REFERENCES
 1 Institute for Health Metrics and Evaluation. Mexico, country profile, 
2017. Available: http://www. healthdata. org/ mexico and http://www. 
healthdata. org/ information- data- availability- gbd- 2019
 2 Campos- Nonato I, Hernández- Barrera L, Pedroza- Tobías A, et al. 
[Hypertension in Mexican adults: prevalence, diagnosis and type of 
treatment. ensanut MC 2016.]. Salud Publica Mex 2018;60:233–43.
 3 Basto- Abreu A, Barrientos- Gutiérrez T, Rojas- Martínez R, et al. 
[Prevalence of diabetes and poor glycemic control in Mexico: results 
from ensanut 2016.]. Salud Publica Mex 2020;62:50–9.
 4 Hernández- Alcaraz C, Aguilar- Salinas CA, Mendoza- Herrera 
K, et al. Dyslipidemia prevalence, awareness, treatment and 
control in Mexico: results of the ensanut 2012. Salud Publica Mex 
2020;62:137–46.
 5 Iglay K, Hannachi H, Joseph Howie P, et al. Prevalence and co- 
prevalence of comorbidities among patients with type 2 diabetes 
mellitus. Curr Med Res Opin 2016;32:1243–52.
 6 Sumin AN, Korok EV, Shcheglova AV, et al. Comorbidities in patients 
with ischemic heart disease: gender differences. Racionalʹnaâ 
farmakoterapiâ v kardiologii 2017;13:622–9.
 7 Metra M, Zacà V, Parati G, et al. Cardiovascular and 
noncardiovascular comorbidities in patients with chronic heart failure. 
J Cardiovasc Med 2011;12:76–84.
 8 Cortaredona S, Ventelou B. The extra cost of comorbidity: multiple 
illnesses and the economic burden of non- communicable diseases. 
BMC Med 2017;15:216.
 9 Aceves B, Ingram M, Nieto C, et al. Non- communicable disease 
prevention in Mexico: policies, programs and regulations. Health 
Promot Int 2020;35:409–21.
 10 Borja- Aburto VH, González- Anaya JA, Dávila- Torres J, et al. 
Evaluation of the impact on non- communicable chronic diseases of 
a major integrated primary health care program in Mexico. Fam Pract 
2016;33:219–25.
 11 Salazar- Coronel AA, Martinez- Tapia B, Mundo- Rosas V, et al. 
Conocimiento y nivel de comprensión de la campaña chécate, 
mídete, muévete en adultos mexicanos. Salud Publica Mex 
2018;60:356–64.
 12 Ambady R, Chamukuttan S. Early diagnosis and prevention of 
diabetes in developing countries. Rev Endocr Metab Disord 
2008;9:193–201.
 13 Harris MI, Eastman RC. Early detection of undiagnosed diabetes 
mellitus: a US perspective. Diabetes Metab Res Rev 2000;16:230–6.
 14 Institute of Medicine, The Health Care Delivery System. The future 
of the public’s health in the 21st century. Washington DC: National 
Academies Press, 2002.
 15 Tapia- Conyer R, Gallardo- Rincón H, Saucedo- Martinez R. 
CASALUD: an innovative health- care system to control and prevent 
non- communicable diseases in Mexico. Perspect Public Health 
2015;135:180–90.
 16 Tapia- Conyer R, Saucedo- Martínez R, Mújica- Rosales R, et al. 
A policy analysis on the proactive prevention of chronic disease: 
learnings from the initial implementation of integrated measurement 
for early detection (MIDO). Int J Health Policy Manag 2017;6:339–44.
 17 Tapia- Conyer R, Gallardo- Rincón H, Saucedo- Martínez R. [Casalud: 
innovations for the transformation of health systems]. Gac Med Mex 
2012;148:567–71.
 18 Lindström J, Tuomilehto J. The diabetes risk score: a practical tool to 
predict type 2 diabetes risk. Diabetes Care 2003;26:725–31.
 19 American Diabetes Association. 2. Classification and diagnosis of 
diabetes: standards of medical care in diabetes-2018. Diabetes Care 
2018;41:S13–27.
 20 Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the 
joint national committee on prevention, detection, evaluation, and 
treatment of high blood pressure. Hypertension 2003;42:1206–52.
 21 World Health Organization. Fact sheet: obesity and overweight: world 
health organization, 2020. Available: https://www. who. int/ news- 
room/ fact- sheets/ detail/ obesity- and- overweight
 22 Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults. Executive summary of the third report of the 
national cholesterol education program (NCEP) expert panel on 
detection, evaluation, and treatment of high blood cholesterol in 
adults (adult treatment panel III). JAMA 2001;285:2486–97.
 23 American Diabetes Association. 6. Glycemic targets: standards of 
medical care in diabetes-2018. Diabetes Care 2018;41:S55–64.
 24 American Diabetes Association. Postprandial blood glucose. 
Diabetes Care 2001;24:775–8.
 25 Chobanian AV, Bakris GL, Black HR, et al. The seventh report of 
the joint National Committee on prevention, detection, evaluation, 
and treatment of high blood pressure: the JNC 7 report. JAMA 
2003;289:2560–72.
 26 Klein S, Allison DB, Heymsfield SB, et al. Waist circumference 
and cardiometabolic risk: a consensus statement from shaping 
america’s health: association for weight management and obesity 
prevention; NAASO, the obesity society; the american society 
for nutrition; and the american diabetes association*. Obesity 
2007;15:1061–7.
 27 Stata. Statistical Software [program]. College Station. TX: StataCorp 
LLC, 2017.
 28 Ritchie GE, Kengne AP, Joshi R, et al. Comparison of near- patient 
capillary glucose measurement and a risk assessment questionnaire 
in screening for type 2 diabetes in a high- risk population in rural 
India. Diabetes Care 2011;34:44–9.
 29 Briney JS, Brown EC, Hawkins JD, et al. Predictive validity of 
established cut points for risk and protective factor scales from the 
communities that care youth survey. J Prim Prev 2012;33:249–58.
 30 World Health Organizaion. Tracking universal health coverage: first 
global monitoring report: world health organisation, 2015. Available: 
https://www. who. int/ healthinfo/ universal_ health_ coverage/ report/ 
2015/ en/
 31 de Waard A- KM, Wändell PE, Holzmann MJ, et al. Barriers and 
facilitators to participation in a health check for cardiometabolic 
diseases in primary care: a systematic review. Eur J Prev Cardiol 
2018;25:1326–40.
 32 Clark CM, Fradkin JE, Hiss RG, et al. Promoting early diagnosis 
and treatment of type 2 diabetes: the national diabetes education 
program. JAMA 2000;284:363–5.
 33 Li R, Zhang P, Barker LE, et al. Cost- Effectiveness of interventions to 
prevent and control diabetes mellitus: a systematic review. Diabetes 
Care 2010;33:1872–94.
 34 Gyawali B, Hansen MRH, Povlsen MB, et al. Awareness, prevalence, 
treatment, and control of type 2 diabetes in a semi- urban area of 
Nepal: findings from a cross- sectional study conducted as a part of 
COBIN- D trial. PLoS One 2018;13:e0206491.
 35 Kayyali R, Slater N, Sahi A, et al. Type 2 diabetes: how informed are 
the general public? A cross- sectional study investigating disease 
awareness and barriers to communicating knowledge in high- risk 
populations in London. BMC Public Health 2019;19:138.
 36 Menke A, Casagrande S, Avilés- Santa ML, et al. Factors 
associated with being unaware of having diabetes. Diabetes Care 
2017;40:e55–6.
 37 Man REK, Gan AHW, Fenwick EK, et al. Prevalence, determinants 
and association of unawareness of diabetes, hypertension and 
hypercholesterolemia with poor disease control in a multi- ethnic 
Asian population without cardiovascular disease. Popul Health Metr 
2019;17:17.
 38 Zgibor JC, Songer TJ. External barriers to diabetes care: 
addressing personal and health systems issues. Diabetes Spectrum 
2001;14:23–8.
 39 Heydarabadi AB, Mehr HM, Nouhjah S. Why rural diabetic patients 
do not attend for scheduled appointments: results of a qualitative 
study. Diabetes Metab Syndr 2017;11 Suppl 2:S989–95.
 40 Peel E, Parry O, Douglas M, et al. Diagnosis of type 2 diabetes: a 
qualitative analysis of patients' emotional reactions and views about 
information provision. Patient Educ Couns 2004;53:269–75.
 41 Carrillo- Balam G, Cantoral A, Rodríguez- Carmona Y, et al. Health- 
care coverage and access to health care in the context of type 2 
diabetes and hypertension in rural Mexico: a systematic literature 
review. Public Health 2020;181:8–15.
 42 Instituto Nacional de Salud Pública. Encuesta nacional de salud 
Y nutrición: secretaría de salud, instituto nacional de estadística 
geografía e informática, instituto nacional de salud pública, 2018. 
Available: https:// ensanut. insp. mx/ encuestas/ ensanut2018/ doctos/ 
informes/ ensanut_ 2018_ presentacion_ resultados. pdf
 43 Rojas- Martínez R, Aguilar- Salinas CA, Jiménez- Corona A. Prevalence 
of obesity and metabolic syndrome components in Mexican 
adults without type 2 diabetes or hypertension. Salud Publica Mex 
2012;54:7–12.
10 Gallardo- Rincón H, et al. BMJ Open 2021;11:e049836. doi:10.1136/bmjopen-2021-049836
Open access 
 44 Ureña- Bogarín EL, Martínez- Ramírez HR, Torres- Sánchez JR, et al. 
Prevalence of pre- diabetes in young Mexican adults in primary health 
care. Fam Pract 2015;32:159–64.
 45 Instituto Nacional de Salud Pública. Encuesta nacional de salud y 
nutrición de medio camino 2016, 2016. Available: https:// ensanut. 
insp. mx/ encuestas /ensanut2016/ index. php
 46 Gaede P, Valentine WJ, Palmer AJ, et al. Cost- effectiveness of 
intensified versus conventional multifactorial intervention in type 2 
diabetes: results and projections from the steno-2 study. Diabetes 
Care 2008;31:1510–5.
 47 Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, 
Blackwell L, et al. Efficacy and safety of more intensive lowering of 
LDL cholesterol: a meta- analysis of data from 170,000 participants in 
26 randomised trials. Lancet 2010;376:1670–81.
 48 Narayan KMV, Chan J, Mohan V. Early identification of type 
2 diabetes: policy should be aligned with health systems 
strengthening. Diabetes Care 2011;34:244–6.
 49 Secretaría de Salud. Norma para La prevención, tratamiento Y 
control de la diabetes mellitus, 2010. Available: http://www. dof. gob. 
mx/ normasOficiales/ 4215/ salud/ salud. htm
 50 Bello- Chavolla OY, Bahena- López JP, Antonio- Villa NE, et al. 
Predicting mortality due to SARS- CoV-2: a mechanistic score relating 
obesity and diabetes to COVID-19 outcomes in Mexico. J Clin 
Endocrinol Metab 2020;105:2752–61.
 51 Bello- Chavolla OY, González- Díaz A, Antonio- Villa NE. Unequal 
impact of structural health determinants and comorbidity on 
COVID-19 severity and lethality in older Mexican adults: looking 
beyond chronological aging, 2020. Available: https://www. medrxiv. 
org/ content/ 10. 1101/ 2020. 05. 12. 20098699v1
 52 Knapp S. Diabetes and infection: is there a link?--A mini- review. 
Gerontology 2013;59:99–104.
 53 Petrie JR, Guzik TJ, Touyz RM, Diabetes TRM. Diabetes, 
hypertension, and cardiovascular disease: clinical insights and 
vascular mechanisms. Can J Cardiol 2018;34:575–84.
 54 Harron K, Dibben C, Boyd J, et al. Challenges in administrative data 
linkage for research. Big Data Soc 2017;4:205395171774567.
